Circling Back to RNA Vaccines: Assessing the Clinical Potential of circRNA
This article from Nature Biotechnology examines the emerging role of circular RNA (circRNA) as a potential successor or complement to linear mRNA vaccines. While circRNA is theoretically superior due to its covalently closed structure, which offers greater stability and resistance enzymatic degradation, its real-world clinical advantages remain largely unproven. The text highlights that while mRNA vaccines have successfully expanded into various infectious disease and cancer applications, circRNA faces uncertainty regarding its ability to translate molecular stability into meaningful clinical gains. However, circRNA shows particular promise in cancer immunotherapy, especially for personalized neoantigen vaccines and treating 'cold' tumors. Its capacity for sustained antigen presentation aligns well with the need for robust cytotoxic T cell responses in oncology. Recent mouse model studies indicate that small circRNA vaccines may offer longer shelf lives, stronger immune responses, and better tolerance compared to mRNA counterparts. Despite these promising preclinical results, it remains unclear whether circRNA will surpass mRNA technology or successfully navigate clinical trials. The analysis suggests that while circRNA is a compelling next-generation platform, further evidence is required to confirm its superiority over established mRNA technologies in human applications.
Wire timeline
Circling Back to RNA Vaccines: Assessing the Clinical Potential of circRNA
This article from Nature Biotechnology examines the emerging role of circular RNA (circRNA) as a potential successor or complement to linear mRNA vaccines. While circRNA is theoretically superior due to its covalently closed structure, which offers greater stability and resistance enzymatic degradation, its real-world clinical advantages remain largely unproven. The text highlights that while mRNA vaccines have successfully expanded into various infectious disease and cancer applications, circRNA faces uncertainty regarding its ability to translate molecular stability into meaningful clinical gains. However, circRNA shows particular promise in cancer immunotherapy, especially for personalized neoantigen vaccines and treating 'cold' tumors. Its capacity for sustained antigen presentation aligns well with the need for robust cytotoxic T cell responses in oncology. Recent mouse model studies indicate that small circRNA vaccines may offer longer shelf lives, stronger immune responses, and better tolerance compared to mRNA counterparts. Despite these promising preclinical results, it remains unclear whether circRNA will surpass mRNA technology or successfully navigate clinical trials. The analysis suggests that while circRNA is a compelling next-generation platform, further evidence is required to confirm its superiority over established mRNA technologies in human applications.
Nature Biotechnology